Brimonidine battle begins with B&L launch
- Generics: Not All Drugs Are Created Equal. Cantor, Louis B.; Lee, David A.; Netland, Peter A. // Review of Ophthalmology;Jan2002, Vol. 9 Issue 1, p72
Evaluates the effectiveness of generic ophthalmic drugs. Categorization of pharmaceuticals; Concerns about generic ophthalmic drugs; Bioequivalence of generic and brand name ophthalmic drugs. INSET: Evolution of United States Generic Drug Policy.
- When Generic Drugs Are Not the Right Rx. Fiscella, Richard G. // Review of Optometry;8/15/2002, Vol. 139 Issue 8, p51
Explains how ophthalmic generic drugs may differ from branded products. Problems with generic ophthalmic products; Overview of the Drug Price Competition and Patent Term Restoration Act; Assessment of drug pharmacokinetics and bioaequivalence; Examples of generic products that have not lived up...
- Generic glaucoma drugs may not offer same effect as brand. Guttman, Cheryl // Ophthalmology Times;4/1/2002, Vol. 27 Issue 7, p1
Reveals that there is insufficient data to determine whether generic glaucoma drugs are equivalent in efficacy and safety relative to the reference legend drug. Economic impact of generic prescribing; Establishment of generic equivalency of ophthalmic products.
- Generics: Friend or Foe? Bowling, Ernie // Review of Optometry;2/15/2011, Vol. 148 Issue 2, p82
The article provides information concerning generic medications, highlighting the crucial role of optometrists to consider ophthalmic generics' therapeutic efficacy and safety characteristics before conducting treatment in the U.S. It mentions the acceptance and usage of generic medications in...
- Topical Ophthalmic Generics: They're Back. Jackson, Mitch // Review of Ophthalmology;Jun2010, Vol. 17 Issue 6, p67
The article discusses the re-emergence of topical ophthalmic nonsteroidal anti-inflammatory drugs (NSAID) generics despite the voluntary recall of generic diclofenac a decade ago. The cost benefit is singled out as one of the reasons of the re-emergence. It mentions that the newest NSAID out in...
- Allergan enters patent battle over generic version of brimonidine tartrate solution. Webb, Jennifer A. // Ophthalmology Times;9/15/2004, Vol. 29 Issue 18, p6
Reports that Allergan Inc. has filed a lawsuit against Alcon Laboratories Inc., claiming that the latter infringed upon the former's patents for brimonidine tartrate ophthalmic solution to manufacture a generic alternative to its Alphagan P drops. Details of the case; Comments from both parties.
- Generic medications in ophthalmology. Zore, Matt; Harris, Alon; Tobe, Leslie Abrams; Siesky, Brent; Januleviciene, Ingrida; Behzadi, Jennifer; Amireskandari, Annahita; Egan, Patrick; Garff, Kevin; Wirostko, Barbara // British Journal of Ophthalmology;Mar2013, Vol. 97 Issue 3, p253
The purpose of this review is to discuss the process of genericisation of medications in the US and Europe with a focus on ophthalmic drugs. Regulatory guidelines of the US Food and Drug Administration and the European Medicines Agency will be discussed, and the advantages and concerns of...
- To what extent does a lack of refrigeration of generic chioramphenicol eye-drops used in India decrease their purity and what are the implications for Europe? Aboshiha, J.; Weir, R.; Singh, P.; Ewings, P.; Lovering, A. // British Journal of Ophthalmology;May2008, Vol. 92 Issue 5, p609
Background/aims: Thermal degradation of chloramphenicol occurs at a faster rate when stored in unrefrigerated conditions. This study measures the concentration of the principal thermal breakdown product of generic chloramphenicot eye-drops being sold over the counter in chemists in different...
- Press FDA to balance disparities among branded drugs, generics. DePaolis, Michael D. // Primary Care Optometry News;May2014, Vol. 19 Issue 5, p3
The article discusses the inequalities between branded and generic medications for use in eye care and the steps taken by the U.S. Food and Drug Administration to address this issue since the Waxman-Hatch Act in 1984.